乳腺癌治疗中短暂性液体潴留与淋巴水肿在淋巴显微外科中的差异
本研究比较乳腺癌相关淋巴水肿(BCRL)与短暂性液体潴留患者的特征,BCRL组168例、液体潴留组73例。BCRL组腋窝淋巴结清扫率96.4%、淋巴结放疗率51.8%,均显著高于液体潴留组的53.4%和24.7%(P均<0.001);液体潴留组紫杉烷类化疗率100%,显著高于BCRL组的92.9%(P=0.02)。作者认为淋巴显微外科应在吲哚菁绿淋巴造影确诊后进行,紫杉烷类化疗所致液体潴留需等待至少6个月。
要点
- BCRL组腋窝淋巴结清扫率96.4%、淋巴结放疗率51.8%,均显著高于液体潴留组。
- 液体潴留组紫杉烷类化疗率100%,显著高于BCRL组的92.9%。
- 淋巴显微外科应在吲哚菁绿淋巴造影确诊后进行,紫杉烷类化疗后至少等待6个月。
核心结论
- 淋巴显微外科应在吲哚菁绿淋巴造影确诊后进行,尤其针对紫杉烷类化疗所致液体潴留患者。
- 紫杉烷类化疗引起的全身性肿胀在化疗后6个月消退,应等待至少6个月再行淋巴显微外科。
研究设计与样本
- 研究将研究对象分为BCRL组和液体潴留组,比较年龄、体重指数、侧别、手术类型(淋巴结、乳腺或无手术)、疾病分期、区域淋巴结照射、激素治疗、化疗类型(紫杉烷类或非紫杉烷类)及曲妥珠单抗治疗。
主要发现
- BCRL组和液体潴留组分别有168例和73例患者。
- BCRL组腋窝淋巴结清扫率96.4%、淋巴结放疗率51.8%,均显著高于液体潴留组的53.4%和24.7%(P均<0.001)。
- 液体潴留组紫杉烷类化疗率100%,显著高于BCRL组的92.9%(P=0.02)。
- 包括激素治疗和曲妥珠单抗治疗在内的其他特征无显著差异。
关键数值与推荐
- 吲哚菁绿淋巴造影显示线性表现且无淋巴功能障碍的短暂性液体潴留患者,不需要淋巴显微外科。
临床怎么用
- 作者认为淋巴显微外科应在吲哚菁绿淋巴造影确诊后进行。
- 作者认为紫杉烷类化疗所致液体潴留患者应等待至少6个月再行淋巴显微外科。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Breast cancer-related lymphedema (BCRL) is a common complication. Repeated taxane-based chemotherapy has been shown to induce endothelial inflammation, leading to fluid retention. Patients with transient fluid retention only have upper limb edema without lymphatic dysfunction. Therefore, indocyanine green lymphography revealed linear findings, and lymphatic microsurgery is not required. This study aimed to investigate the difference between BCRL and fluid retention and present the indication for lymphatic microsurgery for these patients. METHODS: The study population was divided into BCRL and fluid retention groups. Age, body mass index, laterality, surgery type (lymph node, breast, or no surgery), disease stage, regional lymph node irradiation, hormone therapy, chemotherapy type (taxane- or non-taxane-based group), and treatment with trastuzumab were compared. RESULTS: The BCRL and fluid retention groups consisted of 168 and 73 patients, respectively. The BCRL group had significantly higher rates of axillary lymph node dissection (96.4%) and lymph node irradiation (51.8%) than the fluid retention group (53.4% and 24.7%, respectively; P < 0.001 for both). The fluid retention group had a significantly higher rate of taxane-based chemotherapy (100%) than the BCRL group (92.9%; P = 0.02). No significant differences in other characteristics, including treatments with hormone and trastuzumab, were observed. CONCLUSIONS: Lymphatic microsurgery should be performed after confirming the diagnosis by indocyanine green lymphography, particularly for patients with fluid retention induced by taxane-based chemotherapy. Because the generalized swelling induced by taxane-based chemotherapy is resolved 6 months after chemotherapy, we should wait at least 6 months to perform lymphatic microsurgery.
引用
- Tokumoto H, Akita S, Kosaka K, et al. Differences in Transient Fluid Retention and Lymphedema With Breast Cancer Treatment for Lymphatic Microsurgery. Ann Plast Surg. 2023. PMID: 37450868. doi:10.1097/SAP.0000000000003623
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。